Nanotechnology Company Completes Patient Recruitment for Glioblastoma Study

MagForce Nanotechnologies AG (FWB:MF6) has successfully completed patient recruitment for its study on recurrent glioblastoma, which is of critical importance for demonstrating the efficacy of its proprietary Nano-Cancer® therapy. The results of this phase II clinical trial will serve as the basis for the conformity evaluation procedure required under the German Medical Devices Act (Medizinproduktegesetz).

“The completion of patient recruitment is a further milestone on the way to receiving CE European conformity marking for the therapeutic procedure we have developed through which tumors can be specifically and accurately heated and destroyed from the inside out. We plan on preparing the statistical data in the fourth quarter of 2009, as soon as enough patients have concluded the post-observation period or have otherwise reached the study endpoint, so that we will be able to have the product file put together before the end of this year. Once we have received the CE marking, which certifies conformity with health and safety regulations throughout the European Economic Area, we hope to be in a position already next year to commence marketing of Nano-Cancer® therapy throughout Europe,” said Dr. Uwe Maschek, CEO of MagForce Nanotechnologies AG.

MagForce Nanotechnologies AG is the world’s leading company in the area of nanotechnology-based cancer treatment. Its patented Nano-Cancer® therapy allows the targeted destruction of tumors using superparamagnetic nanoparticles to generate heat. The nanotechnology from MagForce represents a revolutionary approach to the future successful treatment of solid tumors.